In the last week, Japan and India have also recommended approval of Merck's experimental pill, which has already been approved in Britain, Denmark and the Philippines, among others, while South Korea on Monday authorised Pfizer's treatment for emergency use.
Merck has signed deals to sell about nine million courses of its treatment to governments around the world, but on Dec 22 France became the first country to publicly say it had cancelled its order following disappointing trial data. It hopes instead to receive Pfizer's drug before the end of January.
In the European Union, both treatments are under review by the European Medicines Agency (EMA), though the regulator has said they can be used in adults ahead of any wider recommendation.
TIMING OF SOURCE DELIVERY
600,000 - 1 million doses
1.6 million courses
100-150 pesos ($1.97-$2.96) per pill
"at the latest"
$700 per course, total of $2.2 billion
TIMING OF DELIVERY
1 million doses
$530 per course, total of $5.29 billion
by the end of 2021